Antibiotics treatmetn for AML – pro
Treatment of neutropenic fever in AML pateitnswith antibiotics is standard. Fever in the neutropenic host must be interpreted as a sign of
infection, even in the absence of other localizing or systemic symptoms, and must prompt the empiric institution of broad-spectrum antibiotics. Many recent studies have focused on the identification of nonaminoglycoside-containing regimens, with a distinct trend toward the development of single-agent therapies. Several beta-lactam and carbapenem antibiotics (eg, aztreonam
[Azactam], cefepime [Maxipime], ceftazidime, imipenem-cilastatin [Primaxin], or meropenem [Merrem]) offer broad-spectrum activity against gram-negative bacteria (including P aeruginosa) and have therefore been assessed as single-agent therapies in patients with neutropenic fever. These drugs offer an attractive alternative to penicillin- and aminoglycoside-containing regimens because of their wide spectrum of activity against gram-negative bacteria and their favorable toxicity profile, and are supported by guidelines
A.S.Davis et al, Leukemia: An Overview for Primary Care, American Family Physician May 1, 2014
PMID: 23634180
Sasmita Biswal and Chaitali Godnaik, Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards. Ecancermedicalscience. 2013; 7: 310.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: acute myeloid leukemia. http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf (subscription required)., 2018